The Clinical Efficacy of R-CHOP Chemotherapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma.
- Author:
Deok Hwan YANG
1
;
Je Jung LEE
;
Yeo Kyeoung KIM
;
Jeong Rae BYUN
;
Sang Hee CHO
;
Ik Joo CHUNG
;
Hyeoung Joon KIM
;
Jong Gwang KIM
;
Dong Hwan KIM
;
Sang Kyun SOHN
;
Won Sup LEE
;
Young Rok DO
;
Hong Suk SONG
;
Joon Seong PARK
;
Hugh Chul KIM
Author Information
1. Department of Hematology-Oncology, Chonnam National University Medical School, Gwangju, Korea. drjejung@chonnam.ac.kr
- Publication Type:Original Article
- Keywords:
CHOP;
Rituximab;
B-cell lymphoma
- MeSH:
B-Lymphocytes*;
Disease-Free Survival;
Doxorubicin;
Drug Therapy*;
Fever;
Follow-Up Studies;
Humans;
Lymphoma, B-Cell*;
Lymphoma, Non-Hodgkin;
Myalgia;
Neutropenia;
Skin;
Vincristine;
Rituximab
- From:Korean Journal of Hematology
2004;39(2):59-65
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: In combination with standard-dose CHOP (cyclophosphamide, vincristine, adriamycin, and prednisolone), the addition of rituximab produces a better clinical response in the treatment of aggressive B-cell non-Hodgkin's lymphoma (NHL) than CHOP alone. METHODS: Thirty-four patients with previously untreated diffuse large B-cell NHL received at least three or four cycles of rituximab 375 mg/m2 or 500 mg per dose on day 1 of each cycle in combination with CHOP chemotherapy. RESULTS: The median age of patients were 61.5 years (range, 28-83 years). After the end of therapy, twenty-five patients (73.5%) experienced a complete response, four patients (11.8 %) had a partial response, and two patients (5.9%) were classified as having progressive disease. The median follow-up duration was 9.4 months (range, 0.2-19.5 months) and 1-year overall survival and progression free survival was 84.8+/-8.7% and 80.3+/-9.4%, respectively. Two patients (5.9%) experienced fever, myalgia, and skin eruption due to rituximab. Neutropenia of grade 3 or 4 occurred in thirty-one patients (91.2%). CONCLUSION: The benefits of rituximab in combination with CHOP chemotherapy include high response rates and good tolerance. However, further prospective, randomized studies are needed to draw definitive conclusions.
